Company intelligence / Profile preview
Viatris
Canonsburg, Pennsylvania, United Statesviatris.com ↗
- Ownership
- Public · VTRS
- Employees
- ~32000
- Development stage
- Commercial
01
Overview
Global pharmaceutical company formed through Mylan-Upjohn merger, focusing on access to medicines across therapeutic areas with ~1,400 approved molecules[6][10]. Recent strategic shifts include divestitures and ophthalmology/dermatology focus[2][5].
- Therapeutic areas
- PulmonologyCardiovascularOphthalmologyDermatologyInfectious Diseases
- Modalities
- Small moleculesBiosimilarsComplex genericsOTC products
- Industry
- Biotech
02
Drug pipeline
37 assets36 more assets in the full pipeline.
Request access →03
Partnerships
Biocon Biologics ($3.3B biosimilars deal)[2]Idorsia Pharmaceuticals (cenerimod collaboration)[9]Lexicon Pharmaceuticals (sotagliflozin agreement)[9]
Beyond the preview
Go deeper on Viatris.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viatris.